To date, the drug classes that have been studied in the area of swallowing and oropharyngeal dysphagia include transient receptor potential vanilloid 1 (TRPV1) agonists,14, 15, 16, 17, 18, 19, 20 transient receptor potential ankyrin 1 (TRPA1) agonists,21 transient receptor potential melastatin 8 (TRPM8) agonists,22 levodopa,23, 24, 25 other dopaminergic agents,26 calcium blocking agents,27, 28 dopamine D2 receptor antagonists,29 angiotensin‐converting enzyme (ACE) inhibitors,30 beta blockers,31 nitric oxide donors32 and acetylcholinesterase inhibitors.33 Here, ACE is linked to Dysphagia.